| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | EPG |
| Uniprot No | Q6UW88-2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-95aa |
| 氨基酸序列 | AVTVTPPITA QQADNIEGPI ALKFSHLCLE DHNSYCINGA CAFHHELEKA ICRCFTGYTG ERCEHLTLTS YA |
| 预测分子量 | 8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下为关于EPG(如指自噬相关蛋白或特定重组蛋白)的模拟参考文献示例，供参考：
---
1. **文献名称**: *Structural and Functional Analysis of EPG-5 in Autophagosome-Lysosome Fusion*
**作者**: Zhang Y. et al.
**摘要**: 本研究解析了EPG-5蛋白的三维结构，揭示了其通过C端结构域介导自噬体与溶酶体膜融合的分子机制，为治疗EPG-5突变相关疾病(如Vici综合征)提供理论依据。
2. **文献名称**: *Recombinant EPG-3 Expression in E. coli: Optimization and Functional Characterization*
**作者**: Tanaka K. et al.
**摘要**: 报道了一种高效表达重组EPG-3蛋白的大肠杆菌体系，并验证其在体外促进细胞自噬活性的功能，为大规模生产该蛋白用于药物筛选奠定基础。
3. **文献名称**: *EPG-7 Knockout Mice Reveal Critical Roles in Embryonic Development*
**作者**: Lee S. & Wang H.
**摘要**: 通过构建EPG-7基因敲除小鼠模型，发现该蛋白缺失导致胚胎期自噬异常及器官发育缺陷，强调了其在发育生物学中的必要性。
4. **文献名称**: *Therapeutic Potential of Recombinant EPG-6 in Neurodegenerative Disorders*
**作者**: Gupta R. et al.
**摘要**: 实验证明重组EPG-6蛋白可增强神经元细胞的自噬通量，显著缓解阿尔茨海默病模型小鼠的病理表型，提示其作为神经保护剂的潜力。
---
注：以上文献为示例，EPG在不同研究中可能指代不同蛋白(如自噬相关基因产物)。建议根据具体研究背景通过PubMed等数据库检索真实文献。
**Background of EPG Recombinant Proteins**
EPG (Eukaryotic Protein Group) recombinant proteins are engineered biomolecules designed to study and manipulate specific cellular processes, particularly those linked to autophagy and protein quality control. Autophagy, a conserved degradation pathway, eliminates damaged organelles, misfolded proteins, and pathogens to maintain cellular homeostasis. EPG proteins, such as EPG-5 (also known as Ectopic P-Granules Protein 5), play critical roles in autophagosome-lysosome fusion, a key step in autophagy. Mutations in EPG-5 are associated with neurodegenerative disorders like Vici syndrome, underscoring their biological significance.
Recombinant EPG proteins are produced using genetic engineering techniques, where EPG-coding genes are inserted into expression systems (e.g., bacteria, yeast, or mammalian cells) to generate purified, functional proteins. These proteins retain native structural and functional properties, enabling researchers to investigate their interactions, enzymatic activities, and regulatory mechanisms in vitro or in cellular models.
Applications of EPG recombinant proteins span basic research and therapeutic development. They are used to dissect autophagy pathways, model diseases caused by EPG dysfunction, and screen potential drugs targeting autophagy-related disorders. Additionally, their structural analysis via X-ray crystallography or cryo-EM provides insights into mechanistic details, aiding rational drug design.
The development of EPG recombinant proteins reflects advances in proteomics and genetic engineering, offering tools to address fundamental questions in cell biology and translational medicine. Their study holds promise for understanding neurodegeneration, cancer, and metabolic diseases, potentially paving the way for novel therapies targeting autophagy dysregulation.
×
